PPARG and non-small cell lung carcinoma: Han and Roman showed that the specific PPARγ antagonist GW9662 failed to affect rosiglitazone-mediated phosphorylation of AMP-activated protein kinase α in NSCLC cells, which indicate these effects of rosiglitazone are PPARγ-independent [22].